The role of myeloid cells in cancer therapies

@article{Engblom2016TheRO,
  title={The role of myeloid cells in cancer therapies},
  author={Camilla Engblom and Christina Pfirschke and Mikael J. Pittet},
  journal={Nature Reviews Cancer},
  year={2016},
  volume={16},
  pages={447-462}
}
Recent clinical trials have demonstrated the ability to durably control cancer in some patients by manipulating T lymphocytes. These immunotherapies are revolutionizing cancer treatment but benefit only a minority of patients. It is thus a crucial time for clinicians, cancer scientists and immunologists to determine the next steps in shifting cancer treatment towards better cancer control. This Review describes recent advances in our understanding of tumour-associated myeloid cells. These cells… 

Innate myeloid cells in the tumor microenvironment.

Tumor-associated myeloid cells: diversity and therapeutic targeting.

An overview of the recent literature on the ever-growing complexity of the biology of TAMs and TANs and the development of the most promising approaches to target these populations therapeutically in cancer patients is provided.

Myeloid Immune Cells CARrying a New Weapon Against Cancer

The elements that constitute the tumor microenvironment, the features and advantages of these cell subtypes and the latest studies using CAR-myeloid immune cells in solid tumor models are discussed.

Tuning the Tumor Myeloid Microenvironment to Fight Cancer

The tumor microenvironment (TME) of diverse cancer types is often characterized by high levels of infiltrating myeloid cells including monocytes, macrophages, dendritic cells, and granulocytes. These

Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective

This work reviews the current knowledge on the events governing protumoral myelopoiesis, analyzing the mechanisms that drive the expansion of major myeloid subsets, as well as their functional properties, and highlighting recent translational strategies for clinical developments.

Targeting tumor-associated macrophages to synergize tumor immunotherapy

Recent studies investigating the involvement of TAMs in immune checkpoint inhibition, tumor vaccines and adoptive cell transfer therapies are summarized, and the therapeutic potential of targeting TAMs as an adjuvant therapy in tumor immunotherapies is discussed.

Myeloid cell-targeted therapies for solid tumours

Key features of monocyte and macrophage biology that are being explored as potential targets for cancer therapies are highlighted and what aspects of myeloid cells need a deeper understanding to identify rational combinatorial strategies to improve clinical outcomes of patients with cancer are highlighted.

Allies or Enemies—The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment

How distinct myeloid cell types can act as enemies of cancer cells by inducing or enhancing an existing immune response, while others act as strong allies, supporting tumor cells in their malignant growth and establishing an immune evasive TME is described.

Role and Therapeutic Implications of MDSCs in Sarcomas

The known role of myeloid-derived suppressor cells (MDSCs) in creating an immunosuppressive state in the tumor microenvironment is explored and current issues with properly defining this heterogeneous continuum of cells with apparent context dependent phenotypic plasticity are highlighted.
...

References

SHOWING 1-10 OF 252 REFERENCES

The future of immune checkpoint therapy

The way forward for this class of novel agents lies in the ability to understand human immune responses in the tumor microenvironment, which will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

The most pertinent and controversial issues of MDSC biology and their role in promoting cancer progression are discussed and how these cells may be used in the clinic, both as prognostic factors and as therapeutic targets are highlighted.

Neutrophils support lung colonization of metastasis-initiating breast cancer cells

It is demonstrated that neutrophil-derived leukotrienes aid the colonization of distant tissues by selectively expanding the sub-pool of cancer cells that retain high tumorigenic potential and the efficacy of using targeted therapy against a specific tumour microenvironment component is revealed.

Immunogenic cell death in cancer therapy.

It is postulate that ICD constitutes a prominent pathway for the activation of the immune system against cancer, which in turn determines the long-term success of anticancer therapies and its subversion by pathogens.

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

The mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy is identified, pointing to new candidate targets for immune potentiation.

The Emerging Understanding of Myeloid Cells as Partners and Targets in Tumor Rejection

The hypothesis that the antigen-presenting compartment within tumor microenvironments may contain significant numbers of potent allies to be leveraged for immune-based tumor clearance is advanced.

Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice.

It is shown that pre-treatment of mouse and human tumor cells with PNT or with MDSCs inhibits binding of processed peptides to tumor cell-associated MHC, and as a result, tumor cells become resistant to antigen-specific CTLs.
...